Your session is about to expire
← Back to Search
JSI-1187 for Solid Tumors
Study Summary
This trial is testing a new drug, JSI-1187, as a possible treatment for cancer. It will be tested alone and in combination with another drug, dabrafenib. The study is for people with advanced solid tumors that have mutations in the MAPK pathway, which causes the pathway to be overactive.
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 251 Patients • NCT01227889Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a tumor or cancer that has spread to your brain and it is causing symptoms.You have another type of cancer that is currently active and may make it difficult to understand the study results.You have a stomach or intestine problem that could make it hard for your body to absorb the study drug(s).You have had a serious infection that required strong antibiotics through an IV in the past week before starting the study treatment.You have a type of cancer that has spread to other parts of your body, and it can be measured. You are a suitable candidate for trying out new treatments.You cannot take certain medications that strongly block BCRP during the study or 2 weeks before starting the study.If you are taking dabrafenib, you should not take strong inhibitors of CYP2C8 at the same time. These medications can make dabrafenib levels in your body too high.
- Group 1: Part A: JSI-1187 Monotherapy Dose Escalation
- Group 2: Part B: JSI-1187 Plus Dabrafenib Combination Dose Escalation
- Group 3: Part C: JSI-1187 Plus Dabrafenib Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have any other experiments utilized JSI-1187 as a component?
"The University of Chicago Medical Center first researched JSI-1187 in 2012 and 42 trials have been concluded since then. At present, there are 46 studies actively enrolling patients; a large portion of which is taking place at Tucson's medical research facilities."
How many centers are administrating this investigation?
"Currently, this clinical trial is being conducted out of 8 facilities. These locations are found in Tucson, Jacksonville and Phoenix as well as 5 other urban centres. To reduce any necessary travel commitments, it would be advisable to select the closest available site."
How many participants are being recruited for this medical experiment?
"To complete this investigation, JS InnoPharm LLC must recruit 124 participants that satisfy the study's criteria. The trial will be conducted in multiple locations, such as Dana Farber Cancer Institute of Tucson and University of Arizona Comprehensive Cancer Centre from Jacksonville."
Is participation in this experiment still open to new recruits?
"Data on clinicaltrials.gov demonstrates that recruitment for this trial is still ongoing, with the initial posting made on June 18th 2020 and edited as recently as September 1st 2022."
What potential hazards should individuals be aware of when using JSI-1187?
"Due to the limited data on JSI-1187, our internal rating of its safety falls at a 1. This is because this trial has only reached Phase 1 and there is not yet enough evidence supporting both efficacy and security."
Share this study with friends
Copy Link
Messenger